Okay. Welcome, everyone, to our Q4 2022 Update. I hope you've all had a chance to read our shareholder letter at investor.axon.com. Our prepared remarks today are meant to build on the information and tables in that very robust letter. During this call, we will discuss our business outlook and make forward-looking statements. Any forward-looking statements made today are pursuant to and within the meaning of the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These comments are based on our predictions and expectations as of today and are not guarantees of future performance. All forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. We discuss these risks in our SEC filings. And before we turn the call over to Rick, we will play our quarterly earnings video, go ahead and settle in. It's about a 10-minute video.

All right. Thank you, Andre and Angel. Great job. And to our investors, I hope you can feel the passion that comes through in that video. And I'm just so humbled to be a part of this team. And the formula is really work for us is when we focus on one of the most important problems we can solve that gets us solving the things that are also the most valuable problems for our customers. And that ultimately is what puts up the results that you see from last year. So TASER 10 is the most sophisticated, accurate and effective TASER energy weapon we've ever created. It's a huge leap forward. Future generations may simply take for granted the existence of these truly capable less lethal technologies as if they had always existed. And like all technological advancements that drive our society forward, that is our goal. Now the customer reception has been fantastic. We are incredibly humbled to be at the forefront of breakthrough technology and societal change. Our 2022 standout performance with revenue up 38% and strong profitability and cash flow follows multiple years of exceptional results even through difficult macro environments. Axon's history of superior execution can be traced to a few key things: our vision and mission; our long-term strategic thinking, and that attracts just an amazing team of passionate and talented people and our relentless focus on customers, we build upon a solid foundation of customer trust. And finally, our conviction to double down on investments to drive unprecedented change and cumulative growth. A prime example of this is the foresight we had more than a decade ago to start building a software business. In 2022, our recurring high-margin cloud revenue comprised more than 30% of the company total. It's great to see our…

Thanks a lot, Rick. Last August, I talked about four major areas of focus for the back half of 2022. And I'm pleased to report that we delivered on all fronts. First, we are driving discipline and prioritization across the business. We say no to many opportunities. And when we do say yes, we win. The results of our efforts include a phenomenal close to the year with revenue up 44% in the back half and more than 50% in Q4 alone. And then a game-changing product launch of TASER 10 just a few weeks later. The second area I talked about was investing to penetrate our total addressable market. In our shareholder letter today, we introduced a new TAM analysis which outlines a $50 billion opportunity and shows growth in our core markets. That core TAM, which includes our SaaS categories, cameras, professional TASER, Axon Air, VR and a customer base that includes U.S. federal, international and commercial enterprises grew from $34 billion to $45 billion in our updated analysis. Much of the TAM we pursue today is in areas where our investments have helped position us as a leader and as a pioneer. We see ourselves as the best positioned to deliver on the future of policing that Rick discussed a moment ago. Thirdly, I'm very pleased to see us deliver on our promise to generate strong cash flow. For the full year, we delivered $195 million in adjusted free cash flow. This was an 84% conversion on adjusted EBITDA of $232 million. This allowed us to maintain a net cash position roughly flat to last year, while investing CapEx to drive global scale in deploying $83 million in strategic ecosystem investments to ensure we stay at the forefront of industry innovation. Finally, we are assembling a world-class…

Thank you, Josh. It's particularly gratifying to see broad-based strength across the business and our strong 2022 execution. Both software and hardware are driving robust performance. Notably, Axon Cloud now represents about one third of our business, carrying best-in-class metrics on growth and net revenue retention. In 2022, cloud revenue grew 50% to $368 million with a 73% gross margin. Annual recurring revenue has grown to $473 million and the net revenue retention is 121%. In addition, we are incredibly proud of the fantastic job Axon has done selling hardware and subscription bundles. 9% of total revenue in 2022 was tied to a subscription compared to just a few years ago when less than half of revenue was subscription-based. Following on Josh's commentary regarding the GAM opportunity, our updated analysis more closely aligns with our focus as an organization. Axon's core TAM of $45 billion across SaaS categories cameras, professional TASER, Axon Air and VR reflects opportunities and a customer base includes public safety, U.S. federal, international and commercial enterprise. At the same time, the consumer personal protection market remains an opportunity, and I'm currently recruiting for a permanent GM to lead the business. However, as we noted in our shareholder letter, we are refarming our analysis on this market from $18 billion to $5 billion in terms of total TAM. Almost $5 billion is still large opportunity that we're interested in pursuing, but we are rightsizing our focus to better reflect the normal opportunity we see in our core business. You'll also note that in Q4, we recognized $8.5 million of cloud revenue that we had previously underreported. This revenue relates to work that was completed in prior periods and was unrecognized due to our ERP implementation in 2021. While the impact is immaterial to our financials, it did…

Okay. Thank you. And do we have everyone in gallery view? Sami Badri from Credit Suisse.

Just have a couple. First one is for Rick. I think Brent just mentioned that TASER 10 is going to be ramping up in 2023. But one thing I think that you laid out in the video is just the feature set and what TASER 10 actually proposes to a lot of your customers would there be customers that feel very strongly about maybe an early shipment or an early refresh of their actual TASER nonlethal weapon, or would they have to stick to kind of the plan or subscription type time line that they've already signed and are subscribed to?

Well, great question. I would say I have never seen demand this strong in a new TASER launch in my history in the business, which is great news. The subscription model does already have our customers on an upgrade pathway, but I'm working closely with Britney and Josh on a customer-by-customer basis, and we are getting a lot of increase for people that want to upgrade early. And so obviously, the revenue accounting on the -- on our contracts with the multiple deliveries is a bit complex. So we're taking those on a case-by-case basis. But we believe that overall, we will be able to find ways to accommodate customers to be able to take early upgrades in ways that also work for our shareholders and that are profitable for us and help our customers get this capability sooner without the need for any big onetime expenditures by just being able to bring forward and adjust and obviously, we hope they'll also upgrade to some of our other new capabilities that we're launching some of our new VR and other things. So we think this really -- the business model continues to set up a win-win for us and our customers. And one great example is the ability for us to accelerate the upgrade cycles.

Got it. Next one is for Josh. Josh, you talked about how compensation will be measured by four key drivers. One of the drivers was actually selling other products or cross-selling. Will that include ecosystem partners that are part of your Axon cloud feature set also being pulled through in the sales motion? Or is that very isolated to just Axon products and services?

Yes. Great question, Sam. I'd say any time we're a sales agent, there is a revenue impact when we sell through a partner's product. But to set expectations, I think that will be a relatively small part of our overall revenue for next year. So it's part of it. And then when you look at the rep level commission plans, we do have a new product sales team that is essentially compensated in large part in momentum of both new products and partner sales. So that's how we solve for that.

Got it. And then one last one for Brittany. I'm burning for the 500 basis points of expansion by 2025. Is this going to be back half loaded across these three years just because of the comment you made regarding some of the products, well, the comments you made and the comments made in the actual press release regarding margin neutrality for some of these products. And then as they ramp up with software, does that [indiscernible]

I think Sami froze, but I think we got the gist of this question, so we can answer it.

Yes. So I'm taking the gist of the question to be when might we get to that 25% margin. And we're really looking to make sure we get there by 2025, Sami, like there are a bunch of those puts and takes that we're looking at both for 2023. And certainly, part of getting to the OpEx leverage that we've talked about is getting to that $2 billion in revenue. And so we need to pull those levers, and it's nice that we have multiple different levers to get there, both from a gross margin and an OpEx standpoint.

Jonathan Ho at William Blair.

Congratulations on the strong results. I guess I wanted to dig a little bit more into your comments about what's underpinning your confidence for the 2025 guidance. Is there something that's maybe changed with some of your market assumptions or one part of the business that's proving stronger than you anticipated to give you that extra degree of confidence to extend that 20% guidance?

Yes. Thanks, Jonathan. Actually, I think it's very much that we have a lot of confidence in all of our product categories and market categories that continue to grow significantly year-over-year. And as I'm sure you're aware, we talked about in the past that we do measure five-year normalized in as kind of a forward-looking indicator of what revenue will look like into the future and not only on a gross basis, but on a year-over-year basis, and we continue to be optimistic about the results we're seeing and the 5-year bookings growth in that 5-year bookings growth rate. And so it's a combination of seeing a lot of really exciting indicators in our new markets, seeing our new product scale and seeing some of the reinforcements in terms of future revenues that the look into bookings provide.

Excellent, excellent. And then just with regards to the TASER 10 pace of adoption, can you remind us what happened when TASER 7 was released? Do you worry at all about maybe customers delaying orders to purchase the 10 million. Just wondering if there's any sort of linearity that we may worry about here just given the step function improvements that you've made or above step function improvements.

Yes, absolutely. Without going into too much detail there, I think the 10 forecast is exceeding year one of the TASER 7 actuals from five years ago. So we're encouraged to see that and it speaks to the value and utility of the product. I would say that it's something we're managing very closely in terms of both early upgrades and new customer shipments. And it provides certainly on path to meet our guidance for the year. We're going to exceed our guidance for the year, but there are several paths toward that goal as well. So we don't want to get too far out over our skis here. We want to make sure that the product we ship is a very high quality one that scales very well in the field. And as we do that, we'll certainly continue to ship all the other high-demand products that we offer to combine for a really nice year this year.

Next question, Eric Suppiger from JMP.

So a couple of questions here. First off, it looks like your TASER revenue was down sequentially I'm curious, was there any reason for that? And conversely, the Axon Cloud and the sensor revenues were up sharply. What was causing that? And I think you had some supply chain constraints that were a factor last quarter. What happened with those various dynamics?

Yes, absolutely. I think it's just timing of shipments and orders. And I think toward the end of the year as we looked at the year and the upcoming product launch. We wanted to be thoughtful about with a product launch a couple of years away, just maintaining flexibility for our customers as we knew some might be interested in the next one. And so we tried to manage that as best we could. And we're very excited to see the supply chain opening up on fleet. I think you'll notice that was a big item in terms of the volume of fleet that shipped in Q4. We expect that to continue throughout the year. We mentioned some of the supply chain challenges historically. We're cautiously optimistic that we're past kind of most of the storm there and feeling good about having the opportunity to ship certainly record-breaking amounts of Fleet 3 this year and of course, plenty of tasers, body cameras and some of our other solutions as well.

Okay. And then your -- can you give us a general idea of how much of your installed base has been migrated to the TASER 7 at this point?

I don't have the exact number in front of me, but I'd say over the last year, in terms of the amount of CW shipped, TASER 7 was above 80% to 85% of the total there. So I think that speaks to the fact that much of the market had moved over from our legacy smart weapons into TASER 7. And now we have the opportunity to, of course, upgrade all of our early TASER 7 customers. But as Rick mentioned, I think there'll be some that are more recent that will be interested as well. So we're very excited to get as many case tens out there as we can.

Keith Housum at Northcoast.

As we look at the kind of coming out, first off, you guys announced a specific data that's going to be deployed. And then second, if we look at past rollouts of the TASER weapons, there's obviously has been some challenges in terms of the gross margin recognition in those first few quarters. So perhaps you guys going to address steps you guys have taken over the past several years to identify and address the bot issue and what you guys are doing different with this rollout to protect your gross margins.

I think it goes to everything from how we design the product to how we design our manufacturing capabilities. We've talked about how when we get to scale, which will happen in the second half of the year. So we are calling it out as a little bit of a potential headwind in the first half of the year. But as we get to the second half of the year, it will be gross margin neutral. And I think the team learned a lot from the T7 launch and took those learnings into T10 and we're thoughtful and careful on the gross margin front.

It's a little bit there. The Fleet is the first major product to launch under the new regime with Hansberitz running our R&D and John Graf and his team running engineering and building in and others and NPI. And basically, what we saw with Fleet, we injected probably six to 12 months of additional prerelease testing to really validate the product. And that paid off in a big way where Fleet 3 is a very sophisticated product, but it's had among the lowest out-of-the-box return rates and customer bugs reported of any product we've ever shipped and TASER 7 -- I'm sorry, TASER 10 went through very similar. It has been in testing with a highly automated production line for probably 6 to 9 months leading into the launch year. So the level of testing compared to previously when we were maybe a less mature company and still making that transition from the more entrepreneurial days. that there's just a lot more time, effort and expense that goes into the upfront testing, but that is paying dividends in the stability and reliability at which we're able to scale these without some of the challenges we had with T7 in particular, come to mind.

Great. And has the restart shipping?

As on TASER 10 will start shipping in March. .

In March. Okay. And then just if I could, Brian, perhaps you put the context or color regarding the convertible note offering you guys did in terms of plans that you guys have to use that cash?

Yes, of course. One, I would say, as you can tell, because it's been a little bit of time. Now it was very much opportunistic from our side to strengthen the balance sheet and to give ourselves a bit more flexibility from a capital standpoint. And we think we found a time to get attractive terms in the market. So we're very pleased that we were able to proactively get ahead of that. And then I think you heard me talk about how we have been investing in our ecosystem partners, how we might potentially consider M&A as we look going forward. And so we want to make sure that when we find something that is appealing from an M&A standpoint that we're able to be on our front foot and move quickly and smartly going forward on that. We spent a lot of time on that convertible offering talking about what might we look for from an M&A standpoint because that was top of everybody's mind. And so a little color is, I think, if you look at our M&A history historically, that's probably a pretty good indication where we're really looking for either technology or talent that will support our future product road map and/or our moonshot goals and mission.

Paul Chung at JPMorgan.

So just another follow-up on kind of the pace of operating leverage through 2025. The pace accelerates a bit in '24 and '25 to get to that 25%. How do we think about the OpEx base kind of relative to gross margin expansion? And longer term, can you still get to that 30% mark you've mentioned in the past?

Yes. So I think we're really looking at the 3-year guidance that not to say we might not get to 30% at some point. But I think this is really meant to sort of replace that and like, okay, we have a plan in a concrete way to get to 25% by 2025, and then we'll start looking out from beyond there in terms of where we will go. So I wouldn't say we're calling that, but maybe we're phasing that out and focusing on what is actionable and in front of us and what we really see a path to right now, and that's the 25% in 2025. I think you are correctly interpreting that we've got some puts and takes in 2023. And so we're not putting a stake in the ground specifically on any 2023 gross margin guidance. But we do expect to see both improvement on gross margin and OpEx leverage to get to that 25%. Perhaps over time with a little bit more under our belts, we be able to quantify the pieces a bit more. But for right now, we're just really looking on driving both of those together to hit that 25%. And again, it's about 50 basis points of leverage in 2023. So you are all correctly picking up on more of that improvement will come in '24 and '25.

Okay. Great. And then just a follow-up on cash flow. Can you expand on kind of the big upside relative to prior guide and you're above your target kind of conversion rate this year are back in 2022? And then how do we think about free cash flow conversion in '23 and the puts and takes there? And is at least 60% conversion longer term, somewhat conservative given the tough macro backdrop, you guys hit 80% plus mark. Is that -- can we be at that 8% mark pretty consistently?

Yes. No, those are all excellent questions. I might go in reverse order, which is I don't want to say that we'll be at that 80% plus consistently. We're really -- we're looking to be at that 60% plus consistently. And the reason that we're there rather than the 80% plus, even though we did a phenomenal job on free cash flow generation this year is -- if you look at '21, I would say we did a less phenomenal job on free cash flow generation. And so if you look at sort of '21 and '22 together, you actually get back to that roughly 60, 65-ish percent free cash flow generation on average between those two years. And some of the things that lead to that are investing in working capital and investing in inventory as we continue to grow our hardware business, continuing to invest in CapEx like automation. We have a number of those puts and takes that we've looked at and based on places that we are investing in our cash flow. We really think that, that 60% target on an annual basis is what we're looking for, might mean we do better some years. But I think as you look over a 3-year period, and as we've looked back, that's probably the right expectation level to set. While we are growing at the kind of rates we're growing at. So if we are growing at 20% plus anymore, would we revisit that free cash flow target? Yes, certainly. But at those types of top line growth rate, we think that's the right balance in terms of what we're flowing through.

Will Power at Baird.

I've got a couple of questions. I guess I'm going to start with TS-1, probably for either Rick or Josh work, I guess, a little over a month past TASERCon. I wonder if you have any additional feedback comments you could share from agencies that have been using the device in the field, any comments around level of use, effectiveness, et cetera. And I guess the second part would just be with regard to supply chain components for both the devices and cartridges as we move through the year here. A - Rick Smith So I'll start off. We continue to get great feedback from the field. I think we've now had something approaching 40 or so different uses. I think we've had -- the one that I mentioned at TASERCon, where it was fired at a running situation at something like 40 feet and the person stumble forward. and the wires broke, but the agency then closed in the other offset of TASER 7. So ultimately, TASER on the day in that use. We categorize that as a partial effectiveness of the T10. And then we did have only one other case where it was not effective, and that was one where it was in quarter use an offered the first dart and turn out the second officer had not been trained on the TASER 10 yet and actually ran in and got between the operator and the subject before we part second art. And so one of the things we took away from that is actually making sure we work with our partners that they train all officers and how the new system functions. So the good news is we're continuing to see very high effectiveness. We -- since TASERCON, we presented to the major city chiefs and…

Yes, it was just about component availability, I think. Is that right, Will?

Yes, supply chain components, both for devices and cartridges, what does that look like?

Yes, absolutely. So our supply chain team, as always, has just done a fantastic job staying ahead of the curve in what are less challenging times than maybe a year or two ago, but any time you launch a new product, there are a lot of provisions and moving parts leading up to that. And ultimately, we feel really good about our capacity not only this year, but continuing to build out our automation capabilities to more exponentially expand our capacity into the future. And so certainly, we have plenty of inventory to support our revenue guidance and beyond for this year and next year, we're aggressively planning for even higher demand.

Okay. Great. If I could just add a question on software, continued strong traction across Axon Cloud. Maybe kind of two parts there, too. What's kind of driving the continued DIMs adoption? It feels like that continues to accelerate, I guess, in some respects. And I guess, in tandem with that, maybe just any kind of update what you're seeing with respect to records and other products out of kind of the core evidence category?

Maybe I'll start with the dentist question and then hand it over to Jeff for records. But the reason I want to take this one will is to give Jeff a huge shout out for the work he's done over the last few years. He's essentially built a team that not only has delivered on the core ecosystem, but continues to build out the last mile types of features and products that make the product, not only that much more valuable to our core market, but also more attractive to our kind of up-and-coming markets in federal and international. And so his team has just done a great job continuing to identify opportunity and market needs and then executing well on the plan to deliver those capabilities and just that flywheel continues to lend itself to more customer interest and more happy customers that will buy more over time. And so that's been the backbone of our dems adoption. And maybe Jeff, I'll take it over to you on records.

Sure. No, that's awesome to hear and I couldn't agree more about the power of everything we've done to continue to make the overall suite more attractive, both in aggregate and in the piece parts. And I think just building on what Josh said, that also combines with the power of our OSP flywheel model because as we continue to both add new capabilities into the bundles and ad where appropriate new tiers of the bundle that just makes it, again, easier and easier for agencies to make one simple choice to get access to this very Amazon Prime or Microsoft College basket of both hardware and software benefits that they buy at a price that feels great to them even for the subset of the components that they know they want to use upfront. And then as they go forward, all those additional benefits of basket feel free because they've already made the what feels to them like a good deal price for the basket and that drives the flywheel. And on top of that, who aren't yet in those programs, all a care are more and more and more seeing the value of those add-ons and incrementally growing ARPU as well as adding new logos. On the record side, again, we continue to be both humble and really excited and optimistic about the continued growth and trajectory. Just sort of using the same numbers we've talked to you about over the last couple of quarters. with growth. Now we have over 50 agencies that represent over almost 18,000 sworn officers live on at least record one module of Axon Records. And that includes now 16 agencies who are already using the product to fully replace their legacy RMS. And that includes, at this point, major cities such as Tucson and Baltimore, Virginia Beach and Fresno.

We have three analysts left in the queue and [indiscernible]

AJ, just real quick, I think will deserve a shout out for the best T-shirt on the call today. That's the 10 shops and 45 feet from the TASER 10. So great fashion sense.

So we have three analysts left in the queue, and we're happy to go past the top of the hour, so we can make sure we get to everyone. We love the engagement. Jeremy Hamblin, at Craig Hallum.

Congrats on all the momentum in the business. So I just want to start with a high-level question. In terms of thoughts around M&A, strategic investments, you guys have a pretty robust balance sheet, that has been building I wanted to get a sense on terms of what you might be looking at on a go-forward basis in terms of scale, size of potential opportunities, whether it's strategic investment or M&A? And then to get a sense, are there any guidelines that you're looking at in terms of whether or not a deal is accretive or dilutive Obviously, you've kind of changed some of the viewpoints on stock-based comp and so forth, so to reduce future dilution. I wanted to get a sense for how you guys are looking at that.

Yes. No, it's a great question. For us, it really is about either vending technology or teams that fit in well with our mission and/or our business model. And so there are multiple parameters that we are looking to evaluate companies on. And so it's always sort of a multifaceted equation for us as we think through them. That's not to say that we aren't looking at whether or not something is financially attractive to us. but it could be across different metrics. It could significantly increase our TAM. It could help us get conviction on supporting that 20% growth long, long, long term? Or it could be accretive to our gross margins or EBITDA margins. So there isn't sort of one set of things we're looking at, but we're really looking at ways that we can find companies that tuck into our ecosystem. We're looking to really integrate the technology and present a holistic Axon solution as we look forward. And then I'll just note that, that dilution number is really sort of an organic dilution number. So I think we have a strong balance sheet. I think we can certainly use cash for that. If we were going to use equity, I would consider that separately from what we're doing from just an internal stock comp expense standpoint.

Great. That's helpful. Then a couple of product questions. So first, coming back to TASER 10. I wanted to get a sense, you offered some guidelines around bundled pricing. But wanted to get an understanding for versus the TASER 7, what your kind of net ASP might look like on a go-forward basis vis-a-vis kind of 10% higher ASP. Obviously, there may be higher cartridge use given the product. So that's one on the TASER 10. And then secondly, you had a pretty massive quarter in Axon Fleet. I think, by far, almost double what you've ever done in a quarter. In fact, almost as much as you've done in many years. So I wanted to just get an understanding of -- was that a couple of really big orders? Or is there something specific to that product that you've really gained traction and now maybe we're past certain life cycles on prior contracts where you guys are just gaining more share? Any color there would be super helpful.

Yes, absolutely. Thanks a lot for the question. Nice to see you, Jeremy. On TASER 10 ASPs, we're not going to get too prescriptive there, but I'd say you should expect an uplift over previous generations and -- that's part due to the hand price and also part due to the number of cartridges in the bundle relative to previous models. And so I think we published the list prices on the website, so you can kind of derive from that what type of uplift to it will be in our bundles. So there'll be a slight inherent discount associated with any product in a bundle, but at a high level, that's kind of the story with TASER 10. And then with Fleet 3, no outsized orders like just a lot of volume, and you should expect that to continue and and maybe even higher levels this year. The product has great product market fit. It's a well-built, well-designed product. the ALPR functionality associated with it is in high demand. ALPR is one of our fastest-growing software add-ons across the business. I think historically, you might remember our Fleet One system, which was more or less a body cam attached to a windshield and then fleet two was the moment where we got to parity -- but then Fleet 3 was the moment where we really surged ahead of the market and became the highest -- the largest selling in video system and public safety. And so actually, I think that's a path you can expect from a lot of our products over time where we reach parity with one version, and then we really accelerate ahead. And so we're really excited about the progress with Fleet 3, Blake Bullock, our product manager and our entire team on Fleet 3 has just done a fantastic job there, and we're really proud of the progress. Still a lot of work to do, but Encouraging to see that product take shape as the highest demand in-car video system and public safety.

Yes, just a pretty think Fleet 3 is like the perfect example of the power and the beauty of us being both an IoT hardware devices company and a cloud software company under one roof because we can deliver an end-to-end experience that not only functionality-wise, but then economically really feeds off of itself as part of our flywheel. And so not only is Sweet hands down the best straight up hardware and car camera system that's ever been released. But in combination with the revolutionary improvements we made to democratize access to great ALPR, it makes it an extraordinarily attractive software add-on to buy that they can either buy the front or they can easily add at any point later with just the flick of a switch, and the whole thing works end to end the with the rest of our suite. .

We have two folks left. Elisa Shreve is on for Tim Long at Barclays. Elisa, you're off mute, but we're not hearing anything come through Okay. Let's go to Josh Riley from Needham.

It seems like there's more opportunity for you guys to have some competitive takeaways in body cams in the U.S. based on our discussions with customers. Is that what you're seeing today? Or would you characterize more of the growth in 2022 as a greenfield with officers who didn't have a body cam at all?

I think, Josh, the nice part is it's a combination of both. We continue to sell high volumes of body cameras to new customers, but we also continue to see existing customers buy more and deploy more widely. And then, of course, by more and more of our features that are on top of the body camera and so -- in peripheral products like fleet and virtual reality and drones and so forth. So it's a nice healthy mix across the board, and we're very excited about that. We want to diversify the number of ways we can achieve these types of results. And I think we're doing that, and we're very excited about that trend.

Got it. That's helpful. And then can you just remind us, is there any seasonality around any of your products or just the overall business that we should be aware of as we're modeling revenue for 2023? And how could the TASER ramp impact the first couple of quarters of the year's TASER revenue, if at all?

I think, again, like we've got a number of ways to deliver in each quarter. And so it's -- of course, if we start out with strong shipments of TASER 10, then that makes the path easier, but that's not our only path. And so we're excited about the fact that between all of our hardware products and just the growing base of software revenue that we have in the business that we've been thoughtful about our guidance here. We believe it's very achievable. We continue to expect to grow 20% year-over-year and quarter-over-quarter. So we'll continue to to execute here and make sure that between TASER shipments and all of our other products that we're very thoughtful about how we guide.

Yes. And specifically, I would say, Josh, we're not calling out anything unique on the shape of the year. And so I would expect pretty typical seasonality for us. even with T10 coming in, like we still have really nice strong T7 performance. And so we've got a lot of puts and takes to Josh's point, and I would say, for your model, think about normal seasonality.

Elisa, should we try one more time? Okay. Go ahead. Let's have Rick Smith close us out.

All right. Well, again, it's always such a pleasure to be able to share results like this. Josh, Brittany, the whole team, some of the other names you heard, a lot of people working really passionately and hard to turn these results in. And I couldn't be more excited to see how this year unfolds. TASER 10, Fleet 3, our software products really starting to scale themselves as you're seeing in the financial results. So a lot of exciting things look forward to. We look forward to seeing some of you accelerate in April at our shareholder meeting, which I believe is coming up in May. And then we'll be back to share Q1 results here in a few weeks as well. So thanks, everybody. We appreciate the opportunity to work for you on such an amazing mission.

Good bye.